A NEW IMNOVID^® (pomalidomide) TRIPLET

IMNOVID with bortezomib and dexamethasone, PVd

NOW APPROVED IN THE EU

for RRMM as early as first relapse,
post-REVLIMID^® (lenalidomide)¹

Indication
IMNOVID in combination with bortezomib and
dexamethasone is indicated in the treatment
of adult patients with multiple myeloma who
have received at least one prior treatment
regimen including lenalidomide.

RRMM=relapsed/refractory multiple myeloma.

PVd is the first and only triplet specifically
proven in a 100% REVLIMID-exposed RRMM
population as early as first relapse.²

LEARN MORE

References: 1. IMNOVID [Summary of Product Characteristics]. Utrecht, Netherlands, Celgene Europe B.V.; 2019. 2. Dimopoulos M, et al. ASH 2018. Abstract no. 3278.

PVd=IMNOVID+bortezomib+dexamethasone.
03/19 INT-POMA190004